Discontinued — last reported Q2 '24
Amgen Equity Method Income decreased by 55.6% to $12.00M in Q2 2024 compared to the prior quarter. Year-over-year, this metric grew by 142.9%, from -$28.00M to $12.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase reflects strong performance from joint ventures or strategic partners, while a decrease indicates underperformance in those specific investments.
This metric captures the company's proportionate share of the net earnings or losses from investments in unconsolidated...
Common in technology and manufacturing sectors where joint ventures are used for R&D or supply chain integration.
equity_method_income| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$166.00M | -$305.00M | -$192.00M | -$216.00M | -$178.00M | $31.00M | -$28.00M | $14.00M | -$28.00M | $27.00M | $12.00M |
| QoQ Change | — | -83.7% | +37.0% | -12.5% | +17.6% | +117.4% | -190.3% | +150.0% | -300.0% | +196.4% | -55.6% |
| YoY Change | — | — | — | -30.1% | — | +110.2% | +85.4% | +106.5% | +84.3% | -12.9% | +142.9% |
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 |
|---|---|---|---|---|---|---|
| Reportable Segment | $27.00M | $12.00M | -$28.00M | -$11.00M | -$18.00M | $10.00M |
| Total | $27.00M | $12.00M | — | — | — | — |
Reportable Segment was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.